Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients

Figures & data

Table 1 Risk-Benefit Assessment for Chemotherapy in Older Adult Breast Cancer Patients

	Data Source	Predictive Results	Clinical Endpoints	Feasibility in Older Adult Patients
Adjuvant! Online	SEER database	Benefits of chemotherapy and endocrine therapy	Disease-specific deaths; Non-disease-specific deaths	Overestimation of 10-year overall survival and disease-free survival
PREDICT	UK National Cancer Registration database	Benefits of chemotherapy, endocrine therapy, and targeted therapy	Disease-specific deaths	Accurate estimation of 5-year overall survival; Overestimation of 10-year overall survival
21-Gene expression analysis	TAILORx trial	Benefits of chemotherapy in hormone receptor-positive, HER2-negative, node-negative disease	Invasive disease-free survival; Distant recurrence-free interval	Patients over 75 excluded; only 5% of patients were aged 70 or older

Table 2 Models for Predicting Toxicity in Older Adult Breast Cancer Patients Receiving Chemotherapy

	CARG	CRASH
General health variables	Age	Age; BMI; Diastolic blood pressure; ECOG score; Self-rated health
Disease-specific variables	Cancer type	Cancer type, stage, and bone marrow invasion
Treatment-related variables	Chemotherapy regimen and dose	Treatment type (surgery, radiation therapy, chemotherapy, etc.)
Hematologic and biochemical variables	Hemoglobin; Creatinine clearance	WBC; Platelets; Hemoglobin; Aspartate aminotransferase; Lactate dehydrogenase; Albumin
Geriatric assessment variables	Hearing loss; Number of falls in the past 6 months; Ability to take medications; Self-care ability; Ability to walk one block; Social activity level	Nutritional status; Independent living skills; Cognitive impairment; CIRS-G score, etc.